Harbert Fund Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-37,500
Closed -$3.38M 104
2024
Q4
$3.38M Buy
37,500
+35,000
+1,400% +$3.39M 1.75% 16
2024
Q3
$247K Buy
+2,500
New +$246K 0.15% 100

Other funds holding XBI

Harbert Fund Advisors's XBI Position: Q4 2024 in Review

Harbert Fund Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 5,150 shares — an estimated $499K sold.

Harbert Fund Advisors first reported a position in XBI in Q2 2024 and held it in 2 quarters. The position peaked at $510K in Q2 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • Harbert Fund Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • Harbert Fund Advisors sold 5,150 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $499K.
  • Harbert Fund Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2024 and held it in 2 quarters.
  • Harbert Fund Advisors's State Street SPDR S&P Biotech ETF position peaked at $510K in Q2 2024.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Harbert Fund Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.